A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes

E. J. Rhee, W. Y. Lee, K. H. Yoon, S. J. Yoo, I. K. Lee, Sei-Hyun Baik, Y. K. Kim, M. K. Lee, K. S. Park, J. Y. Park, B. S. Cha, H. W. Lee, K. W. Min, H. Y. Bae, M. J. Kim, J. A. Kim, D. K. Kim, Sun Woo Kim

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Aim: The objective of this study was to evaluate the optimal dose, efficacy and safety of a novel dipeptidyl peptidase-4 (DPP-IV) inhibitor, LC15-0444, in Korean subjects with type 2 diabetes mellitus treated by diet and exercise. Methods: This study was a double-blind, randomized, multicenter and parallel-group, dose-range finding study. We enrolled 145 patients (91 men and 54 women) with a median age of 53 years and a median body mass index of 25.1 kg/m2. The median baseline fasting plasma glucose (FPG) was 8.1 mmol/l, the median HbA1c was 7.9% and the median time since the diagnosis of diabetes was 3 years. After 2 weeks of an exercise/diet programme followed by 2 weeks of a placebo period, the subjects were randomized to one of the four following groups for a 12-week active treatment period: placebo and 50, 100 or 200 mg of LC15-0444. Results: All three doses of LC15-0444 significantly reduced the HbA1c from baseline compared to the placebo group (-0.06 vs. -0.98, -0.74 and -0.78% in the placebo and 50, 100 and 200 mg groups, respectively), without a significant difference between the doses. Subjects with a higher baseline HbA1c (-8.5%) had a greater reduction in HbA1c. Insulin secretory function, as assessed using homeostasis model assessment-beta cell, C-peptide and the insulinogenic index, improved significantly with LC15-0444 treatment. Insulin sensitivity, as assessed using homeostasis model assessment-insulin resistance, also improved significantly after 12 weeks of treatment. The 50 and 200 mg groups had significantly reduced total cholesterol and low-density lipoprotein cholesterol levels at 12 weeks compared to the placebo group. No dosage of LC15-0444 affected weight or waist circumference. The incidences of adverse events were similar in all study subjects. Conclusions: LC15-0444 monotherapy (50 mg for 12 weeks) improved the HbA1c, FPG level, oral glucose tolerance test results, β-cell function and insulin sensitivity measures, and was well tolerated in Korean subjects with type 2 diabetes.

Original languageEnglish
Pages (from-to)1113-1119
Number of pages7
JournalDiabetes, Obesity and Metabolism
Volume12
Issue number12
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Type 2 Diabetes Mellitus
Placebos
Safety
Insulin Resistance
Fasting
Homeostasis
Exercise
Diet
Dipeptidyl Peptidase 4
Glucose
C-Peptide
Waist Circumference
Glucose Tolerance Test
LDL Cholesterol
LC15-0444
Body Mass Index
Therapeutics
Cholesterol
Insulin
Weights and Measures

Keywords

  • Dose-finding study
  • DPP-IV inhibitor
  • Monotherapy
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. / Rhee, E. J.; Lee, W. Y.; Yoon, K. H.; Yoo, S. J.; Lee, I. K.; Baik, Sei-Hyun; Kim, Y. K.; Lee, M. K.; Park, K. S.; Park, J. Y.; Cha, B. S.; Lee, H. W.; Min, K. W.; Bae, H. Y.; Kim, M. J.; Kim, J. A.; Kim, D. K.; Kim, Sun Woo.

In: Diabetes, Obesity and Metabolism, Vol. 12, No. 12, 01.12.2010, p. 1113-1119.

Research output: Contribution to journalArticle

Rhee, EJ, Lee, WY, Yoon, KH, Yoo, SJ, Lee, IK, Baik, S-H, Kim, YK, Lee, MK, Park, KS, Park, JY, Cha, BS, Lee, HW, Min, KW, Bae, HY, Kim, MJ, Kim, JA, Kim, DK & Kim, SW 2010, 'A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes', Diabetes, Obesity and Metabolism, vol. 12, no. 12, pp. 1113-1119. https://doi.org/10.1111/j.1463-1326.2010.01303.x
Rhee, E. J. ; Lee, W. Y. ; Yoon, K. H. ; Yoo, S. J. ; Lee, I. K. ; Baik, Sei-Hyun ; Kim, Y. K. ; Lee, M. K. ; Park, K. S. ; Park, J. Y. ; Cha, B. S. ; Lee, H. W. ; Min, K. W. ; Bae, H. Y. ; Kim, M. J. ; Kim, J. A. ; Kim, D. K. ; Kim, Sun Woo. / A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. In: Diabetes, Obesity and Metabolism. 2010 ; Vol. 12, No. 12. pp. 1113-1119.
@article{9d0173840fe44ca388e42d52c5bb8663,
title = "A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes",
abstract = "Aim: The objective of this study was to evaluate the optimal dose, efficacy and safety of a novel dipeptidyl peptidase-4 (DPP-IV) inhibitor, LC15-0444, in Korean subjects with type 2 diabetes mellitus treated by diet and exercise. Methods: This study was a double-blind, randomized, multicenter and parallel-group, dose-range finding study. We enrolled 145 patients (91 men and 54 women) with a median age of 53 years and a median body mass index of 25.1 kg/m2. The median baseline fasting plasma glucose (FPG) was 8.1 mmol/l, the median HbA1c was 7.9{\%} and the median time since the diagnosis of diabetes was 3 years. After 2 weeks of an exercise/diet programme followed by 2 weeks of a placebo period, the subjects were randomized to one of the four following groups for a 12-week active treatment period: placebo and 50, 100 or 200 mg of LC15-0444. Results: All three doses of LC15-0444 significantly reduced the HbA1c from baseline compared to the placebo group (-0.06 vs. -0.98, -0.74 and -0.78{\%} in the placebo and 50, 100 and 200 mg groups, respectively), without a significant difference between the doses. Subjects with a higher baseline HbA1c (-8.5{\%}) had a greater reduction in HbA1c. Insulin secretory function, as assessed using homeostasis model assessment-beta cell, C-peptide and the insulinogenic index, improved significantly with LC15-0444 treatment. Insulin sensitivity, as assessed using homeostasis model assessment-insulin resistance, also improved significantly after 12 weeks of treatment. The 50 and 200 mg groups had significantly reduced total cholesterol and low-density lipoprotein cholesterol levels at 12 weeks compared to the placebo group. No dosage of LC15-0444 affected weight or waist circumference. The incidences of adverse events were similar in all study subjects. Conclusions: LC15-0444 monotherapy (50 mg for 12 weeks) improved the HbA1c, FPG level, oral glucose tolerance test results, β-cell function and insulin sensitivity measures, and was well tolerated in Korean subjects with type 2 diabetes.",
keywords = "Dose-finding study, DPP-IV inhibitor, Monotherapy, Type 2 diabetes",
author = "Rhee, {E. J.} and Lee, {W. Y.} and Yoon, {K. H.} and Yoo, {S. J.} and Lee, {I. K.} and Sei-Hyun Baik and Kim, {Y. K.} and Lee, {M. K.} and Park, {K. S.} and Park, {J. Y.} and Cha, {B. S.} and Lee, {H. W.} and Min, {K. W.} and Bae, {H. Y.} and Kim, {M. J.} and Kim, {J. A.} and Kim, {D. K.} and Kim, {Sun Woo}",
year = "2010",
month = "12",
day = "1",
doi = "10.1111/j.1463-1326.2010.01303.x",
language = "English",
volume = "12",
pages = "1113--1119",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes

AU - Rhee, E. J.

AU - Lee, W. Y.

AU - Yoon, K. H.

AU - Yoo, S. J.

AU - Lee, I. K.

AU - Baik, Sei-Hyun

AU - Kim, Y. K.

AU - Lee, M. K.

AU - Park, K. S.

AU - Park, J. Y.

AU - Cha, B. S.

AU - Lee, H. W.

AU - Min, K. W.

AU - Bae, H. Y.

AU - Kim, M. J.

AU - Kim, J. A.

AU - Kim, D. K.

AU - Kim, Sun Woo

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Aim: The objective of this study was to evaluate the optimal dose, efficacy and safety of a novel dipeptidyl peptidase-4 (DPP-IV) inhibitor, LC15-0444, in Korean subjects with type 2 diabetes mellitus treated by diet and exercise. Methods: This study was a double-blind, randomized, multicenter and parallel-group, dose-range finding study. We enrolled 145 patients (91 men and 54 women) with a median age of 53 years and a median body mass index of 25.1 kg/m2. The median baseline fasting plasma glucose (FPG) was 8.1 mmol/l, the median HbA1c was 7.9% and the median time since the diagnosis of diabetes was 3 years. After 2 weeks of an exercise/diet programme followed by 2 weeks of a placebo period, the subjects were randomized to one of the four following groups for a 12-week active treatment period: placebo and 50, 100 or 200 mg of LC15-0444. Results: All three doses of LC15-0444 significantly reduced the HbA1c from baseline compared to the placebo group (-0.06 vs. -0.98, -0.74 and -0.78% in the placebo and 50, 100 and 200 mg groups, respectively), without a significant difference between the doses. Subjects with a higher baseline HbA1c (-8.5%) had a greater reduction in HbA1c. Insulin secretory function, as assessed using homeostasis model assessment-beta cell, C-peptide and the insulinogenic index, improved significantly with LC15-0444 treatment. Insulin sensitivity, as assessed using homeostasis model assessment-insulin resistance, also improved significantly after 12 weeks of treatment. The 50 and 200 mg groups had significantly reduced total cholesterol and low-density lipoprotein cholesterol levels at 12 weeks compared to the placebo group. No dosage of LC15-0444 affected weight or waist circumference. The incidences of adverse events were similar in all study subjects. Conclusions: LC15-0444 monotherapy (50 mg for 12 weeks) improved the HbA1c, FPG level, oral glucose tolerance test results, β-cell function and insulin sensitivity measures, and was well tolerated in Korean subjects with type 2 diabetes.

AB - Aim: The objective of this study was to evaluate the optimal dose, efficacy and safety of a novel dipeptidyl peptidase-4 (DPP-IV) inhibitor, LC15-0444, in Korean subjects with type 2 diabetes mellitus treated by diet and exercise. Methods: This study was a double-blind, randomized, multicenter and parallel-group, dose-range finding study. We enrolled 145 patients (91 men and 54 women) with a median age of 53 years and a median body mass index of 25.1 kg/m2. The median baseline fasting plasma glucose (FPG) was 8.1 mmol/l, the median HbA1c was 7.9% and the median time since the diagnosis of diabetes was 3 years. After 2 weeks of an exercise/diet programme followed by 2 weeks of a placebo period, the subjects were randomized to one of the four following groups for a 12-week active treatment period: placebo and 50, 100 or 200 mg of LC15-0444. Results: All three doses of LC15-0444 significantly reduced the HbA1c from baseline compared to the placebo group (-0.06 vs. -0.98, -0.74 and -0.78% in the placebo and 50, 100 and 200 mg groups, respectively), without a significant difference between the doses. Subjects with a higher baseline HbA1c (-8.5%) had a greater reduction in HbA1c. Insulin secretory function, as assessed using homeostasis model assessment-beta cell, C-peptide and the insulinogenic index, improved significantly with LC15-0444 treatment. Insulin sensitivity, as assessed using homeostasis model assessment-insulin resistance, also improved significantly after 12 weeks of treatment. The 50 and 200 mg groups had significantly reduced total cholesterol and low-density lipoprotein cholesterol levels at 12 weeks compared to the placebo group. No dosage of LC15-0444 affected weight or waist circumference. The incidences of adverse events were similar in all study subjects. Conclusions: LC15-0444 monotherapy (50 mg for 12 weeks) improved the HbA1c, FPG level, oral glucose tolerance test results, β-cell function and insulin sensitivity measures, and was well tolerated in Korean subjects with type 2 diabetes.

KW - Dose-finding study

KW - DPP-IV inhibitor

KW - Monotherapy

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=77958577337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958577337&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2010.01303.x

DO - 10.1111/j.1463-1326.2010.01303.x

M3 - Article

C2 - 20977584

AN - SCOPUS:77958577337

VL - 12

SP - 1113

EP - 1119

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 12

ER -